Seeking clarification of osteoporosis guidelines

The recent recommendation statement of the Canadian Task Force on Preventive Health Care regarding prevention of osteoporosis and osteoporotic fractures in postmenopausal women contains some confusing information. One example is the statement that “Although there is no direct evidence that screening reduces fractures, there is good evidence that screening is effective in identifying postmenopausal women with low bone mineral density and that treating osteoporosis can reduce the risk of fractures in this population.” This wording appears to have been chosen to obfuscate the meaning, since low bone mineral density, particularly in the younger population, does not strongly correlate with fracture risk or osteoporosis.

Other parts of the recommendation statement do not appear particularly practical. For example, the algorithm shown in Fig. 1 of the article suggests that all women 65 years of age or older should undergo repeat dual-energy x-ray absorptiometry (DEXA) every 1 to 2 years, regardless of the result of initial DEXA (even if that result is normal). Admittedly, this agrees with the guidelines of the US Preventive Services Task Force and the Osteoporosis Society of Canada, but what does it mean for those of us providing primary care? Should we in fact send all of our female patients over age 65, including those in rest homes, for DEXA screening? Would it not be adequate to suggest to women in this age group that they try to exercise regularly and take adequate amounts of vitamin D and calcium?

Also of great concern are the potential medicolegal implications if clinicians do not follow guidelines developed by authoritative bodies such as the Task Force.

Do the CMAJ editors accept guidelines and protocols produced by distinguished Canadian associations (often sponsored by drug companies) without the benefit of peer review or editing?

John Sehmer
Clinical Assistant Professor
University of British Columbia
Vancouver, BC

References

Competing interests: None declared.

DOI:10.1503/cmaj.1040991

The recent recommendation statement concerning the prevention of osteoporosis and osteoporotic fractures in postmenopausal women was developed after a detailed process of identifying the appropriate analytic framework, systematically reviewing the literature, discussing the evidence at multiple Task Force meetings and submitting the statement to 2 levels of peer review (internal peer review within the Task Force and external peer review organized by the Task Force).

On the basis of our analytic framework and the evidence available, we concluded that there is no direct evidence that screening reduces fractures. In other words, there were no acceptable randomized controlled trials that directly evaluated routine screening linked to treatment compared with usual care. However, there is evidence that screening is effective in identifying postmenopausal women with osteoporosis. There is also evidence that treating osteoporosis can reduce the risk of fractures in postmenopausal women. Because the evidence that supports fracture reduction through screening is therefore indirect, our overall recommendation was grade B, rather than grade A. Currently, there is much controversy as to what the treatment threshold should be. Most experts agree that postmenopausal women with osteoporosis (T score at or below –2.5) should be treated with pharmacologic therapies, because there is good to fair evidence from randomized controlled trials that such treatment will reduce osteoporotic fractures in this population. Some of these trials have included women with T scores between –2.0 and –2.5.

There is a strong correlation be-
between low bone mineral density (BMD) and fracture risk in postmenopausal women, and the risk increases with age for a given level of BMD. This predictive ability of BMD for fractures is greater than that of blood pressure for stroke and cholesterol level for cardiovascular disease. However, in younger postmenopausal women with low BMD, the absolute risk is low. Therefore, on the basis of the absolute fracture risk, we recommend BMD screening by DEXA for all postmenopausal women starting at age 65 (see Fig. 1 in our original article). If the result of the initial DEXA is normal, we recommend repeating this test in 2 years. On the same basis, we also recommend considering pharmacologic treatment for those over age 65 with T scores between −2.0 to −2.5. Those younger than 65 years of age with T scores above −2.0 have a lower absolute risk of fracture and therefore the corresponding number needed to treat to prevent one fracture is higher.

In our statement, we were explicit that these recommendations do not apply to those in nursing homes, because we limited our systematic review to the community-dwelling population. We did review compounds that were not available in Canada at the time of our submission for publication but for which published evidence was available (e.g., teriparatide and oral pamidronate), as they may become available here sometime in the future. Current evidence suggests that pharmacologic therapies can further reduce fractures in osteoporotic postmenopausal women who are receiving adequate amounts of vitamin D and calcium. Although we recommend regular exercise because it can maintain BMD and reduce falls, no good evidence exists for fracture reduction with regular exercise in this population.

These evidence-based clinical guidelines are meant to guide physicians in discussions with their postmenopausal patients, as each individual woman may have unique risks and preferences. The guidelines need to be interpreted and applied sensibly. In general, clinical practice guidelines are designed to hasten the incorporation of research findings into routine care, but they are usually not the reference for medicolegal action. Most common law rulings in North America and the United Kingdom are based on minimum acceptable standards of clinical care, which are often derived from responsible customary practice, rather than from clinical practice guidelines.


Competing interests: Angela Cheung has received honoraria to participate in CME events partly or fully supported by Eli Lilly, Merck, Proctor & Gamble, Aventis and Novartis; these companies have also contributed unrestricted educational grants in support of Toronto City-wide Osteoporosis Rounds, which Dr. Cheung chairs.

DOI:10.1503/cmaj.1041404

Mapping malaria

Congratulations to Kathryn Suh and colleagues for their recent comprehensive review of malaria. I have 2 corrections for their Fig. 1, the map showing global distribution of malaria. First, malaria is not endemic to Uruguay. Second, in Paraguay, malaria is in fact sensitive (not resistant) to chloroquine.

Tomás A. Orduna
Tropical Medicine Hospital de Infecciosas F.J. Muñiz
Buenos Aires, Argentina

Reference

Competing interests: None declared.
DOI:10.1503/cmaj.1041174

[The authors respond:]

We thank Tomás Orduna for bringing to our attention some inaccuracies in the map illustrating the global distribution of malaria, which appeared in our review article on this disease. He is correct in pointing out that there is no risk of malaria in Uruguay and that only chloroquine-sensitive malaria is present in Paraguay.

As noted in the original figure caption, the map was intended as a visual aid only and was not meant to provide definitive recommendations regarding malaria risk and prophylaxis. Furthermore, malaria risk may vary within a given country, and hence not all travellers to that country will necessarily require malaria prophylaxis. Readers are therefore referred to additional travel medicine resources, such as Health Canada, the US Centers for Disease Control and Prevention and the World Health Organization (as suggested in the original figure caption and listed at the end of our article), for current recommendations regarding country-specific malaria risks and recommended prophylaxis.

Our Fig. 1 was published courtesy of Health Canada’s Committee to Advise on Tropical Medicine and Travel...